Moleculin appoints Roche veteran Adriano Treve as Strategic Advisor for partnerships; AML data unblinding in H2 2025

Moleculin Biotech, Inc.

Adriano Treve, with 40+ years at Roche in senior exec roles including Area Head for Turkey, Russia, Iran, Central Asia, Eastern Europe, appointed Strategic Advisor for partnerships.
Appointment comes ahead of first unblinding of 45 patients in Phase 2B/3 MIRACLE trial with Annamycin for R/R AML in H2 2025.
Second unblinding expected in H1 2026; interest from strategic partners has significantly increased per CEO Walter Klemp.
Mr. Treve joins existing Business Advisor Dennis McNamara (30+ yrs life sciences transactions) to expand partnership opportunities.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.